A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 15, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Cilta-cel

Cilta-cel will be administered as an IV infusion.

DRUG

Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

Lymphodepleting therapy (cyclophosphamide and fludarabine) will be administered intravenously.

Trial Locations (18)

10029

Mount Sinai Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Medical Center, Pittsburgh

28204

Levine Cancer Institute, Charlotte

30322

Emory University, Atlanta

48201

Barbara Ann Karmanos Cancer Institute, Detroit

53226

Medical College Of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

63110

Washington University School Of Medicine, St Louis

66205

Kansas University Medical Center, Westwood

77030

MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

91010

City of Hope, Duarte

94143

University of California San Francisco, San Francisco

94305

Stanford University Medical Center, Stanford

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Janssen Scientific Affairs, LLC

INDUSTRY